Formycon: Start of clinical development program for FYB206; mwb research reiterates to BUY

Formycon AG has achieved another milestone with the launch of the FYB206 Phase I clinical trial. This trial marks the beginning of clinical testing for Formycon's biosimilar to Merck & Co.'s Keytru...